Accéder au contenu
Merck
Toutes les photos(2)

Key Documents

View All Documentation

HCD8MAG-15K

Millipore

MILLIPLEX® Human CD8+ T Cell Magnetic Bead Panel - Immunology Multiplex Assay

Simultaneously analyze multiple cytokine and chemokine biomarkers with Bead-Based Multiplex Assays using the Luminex technology, in human serum, plasma and cell culture samples.

Synonyme(s) :

Human CD8 T cell cytokine panel, Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(2)

About This Item

Code UNSPSC :
12161503
eCl@ss :
32161000
Nomenclature NACRES :
NA.84

Niveau de qualité

200

Espèces réactives

human

Fabricant/nom de marque

Milliplex®

assay range

standard curve range: 0.4-1,500 pg/mL
(IL-6)
standard curve range: 0.5-2,000 pg/mL
(TNFα)
standard curve range: 1-3,500 pg/mL
(MIP-1α)
standard curve range: 1-5,000 pg/mL
(Granzyme B)
standard curve range: 1-5,000 pg/mL
(IFNγ)
standard curve range: 1-5,000 pg/mL
(IL-5)
standard curve range: 10-50,000 pg/mL
(Perforin)
standard curve range: 10-50,000 pg/mL
(sFasL)
standard curve range: 2-10,000 pg/mL
(IL-4)
standard curve range: 2-10,000 pg/mL
(sCD137)
standard curve range: 2-7,500 pg/mL
(IL-13)
standard curve range: 2-7,500 pg/mL
(IL-2)
standard curve range: 20-100,000 pg/mL
(Granzyme A)
standard curve range: 4-15,000 pg/mL
(GM-CSF)
standard curve range: 400-1,650,000 pg/mL
(sFas)
standard curve range: 5-20,000 pg/mL
(IL-10)
standard curve range: 7-30,000 pg/mL
(MIP-1β)

Technique(s)

multiplexing: suitable

Méthode de détection

fluorometric (Luminex xMAP)

Conditions d'expédition

wet ice

Description générale

CD8+ T cells (also known as cytotoxic T cells, cytolytic T cells and killer T cells) belong to a sub-group of T cells capable of inducing the death of infected somatic or tumor cells. T cells that bind weakly to Major Histocompatibility Complex (MHC) self-antigens are positively selected into single-positive CD4+ or CD8+ T cells in the thymus. Those CD8+ T cells that survive and mature after activation become cytotoxic cells, expressing T-cell receptors (TCRs) capable of recognizing specific antigenic peptides bound to Class I MHC molecules and the glycoprotein CD8. Affinity between the CD8 protein and the MHC molecule helps to keep the cytotoxic T cell and target closely bound during antigen specific activation. Once activated, CD8+ T cells are generally classified as having a predefined cytotoxic role within the immune system and undergo IL-2 induced clonal expansion, which increases the number of cells specific for the target antigen. The CD8+ T cells then travel throughout the body in search of antigen-positive somatic/tumor cells.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Cytokines/Chemokines

Spécificité

Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Application

  • Analytes: GM-CSF, sCD137, IFNγ, sFas, sFasL, Granzyme A, Granzyme B, IL-2, IL-4, IL-5, IL-6, IL-10, IL-13, MIP-1α, MIP-1β, TNF-α, Perforin
  • Recommended Sample type: serum, plasma or tissue/cell lysate and culture supernatant
  • Recommended Sample dilution: Neat
  • Assay Run Time: Overnight
  • Research Category Inflammation & Immunology

Caractéristiques et avantages

Design your multiplex kit by choosing available analytes within this panel.

Stockage et stabilité

Recommended storage for kit components is 2 - 8°C.

Autres remarques

Sensitivity: Refer to kit protocol for sensitivities of individual biomarkers.

Informations légales

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Clause de non-responsabilité

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2

Organes cibles

Respiratory Tract

Code de la classe de stockage

10 - Combustible liquids

Classe de danger pour l'eau (WGK)

WGK 3

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Wiebke Naujoks et al.
Frontiers in immunology, 11, 573200-573200 (2020-10-27)
Obesity is associated with an increased risk for several cancer types and an altered phenotype and functionality of natural killer (NK) cells. This study aimed to investigate the association of overweight and obesity with NK cell functions and receptor expression
Arturo Panduro et al.
Clinical liver disease, 19(2), 41-48 (2022-03-22)
Content available: Author Interview and Audio Recording.
Antti Hurme et al.
Frontiers in immunology, 13, 869990-869990 (2022-05-10)
The emergence of novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has made it more difficult to prevent the virus from spreading despite available vaccines. Reports of breakthrough infections and decreased capacity of antibodies to neutralize variants
Chaoxu Zhang et al.
Frontiers in oncology, 10, 760-760 (2020-06-13)
Anti-PD-1 therapy has been approved for cancer treatment. However, the response rate is unsatisfactory. The expression of PD-L1 in tumor tissues is unreliable to predict the treatment response. Recent studies have suggested that exosomal PD-L1 not only exerts immunosuppressive effects
Emily Han-Chung Hsiue et al.
Science (New York, N.Y.), 371(6533) (2021-03-03)
TP53 (tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as TP53, are not yet available. Here, we describe the identification of an antibody highly specific to the most
Afficher tous les articles scientifiques apparentés

Contenu apparenté

Immunology Multiplex Assays | MILLIPLEX® Assays

Immunology multiplex assays, like MILLIPLEX® assays, allow researchers to investigate more immune biomarkers simultaneously, saving time and resources. This is especially critical to immunology research, where numerous analytes play a role in different pathways.

Multiplexing Inflammation Signaling Pathways | MILLIPLEX® Assays

See how multiplexing the inflammation signaling pathway with MILLIPLEX® inflammation assays or cell signaling assays can help researchers bridge the gap between immunology and cell signaling, including investigating T cell signaling, Th Cell differentiation, inflammatory response signaling, and sepsis signaling.

Multiplex Assays for COVID-19 (SARS-CoV-2) Research Applications | MILLIPLEX® Assays

See how MILLIPLEX® multiplex immunoassays offer researchers the ability to simultaneously quantitate a large number of human cytokines, chemokines, and growth factors, and detect human immunoglobulins against SARS-CoV-2 antigens, to better understand the immune response to COVID-19, including cytokine storm.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique